Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Phase 3

Completed

Conditions: Dengue Fever
Dengue Hemorrhagic Fever

Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

First Posted Date: 2010-12-06

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 250

Registration Number: NCT01254422

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Phase 3

Terminated

Conditions: Multiple Sclerosis Relapse

Interventions: Drug: Teriflunomide
Drug: Placebo (for teriflunomide)
Drug: Interferon-beta (IFN-beta)

First Posted Date: 2010-12-03

Last Posted Date: 2014-06-09

Lead Sponsor: Sanofi

Target Recruit Count: 534

Registration Number: NCT01252355

Locations: 🇨🇴
Investigational Site Number 170001, Barranquilla, Colombia
🇨🇴
Investigational Site Number 170007, Bogota, Colombia
🇪🇪
Investigational Site Number 233002, Tallinn, Estonia

and more 182 locations

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

Phase 3

Withdrawn

Conditions: Hepatic Neoplasm Malignant

Interventions: Drug: oxaliplatin (SR96669)
Drug: capecitabine
Drug: sorafenib

First Posted Date: 2010-11-22

Last Posted Date: 2011-11-09

Lead Sponsor: Sanofi

Registration Number: NCT01245582

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: fexofenadine/Allegra (M016455)

First Posted Date: 2010-11-19

Last Posted Date: 2013-10-16

Lead Sponsor: Sanofi

Target Recruit Count: 100

Registration Number: NCT01244230

Locations: 🇯🇵
Investigational Site Number 392008, Osaka-Shi, Japan
🇯🇵
Investigational Site Number 392005, Setagaya-Ku, Japan
🇯🇵
Investigational Site Number 392004, Setagaya-Ku, Japan

and more 10 locations

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)

Phase 2

Completed

Conditions: Rhinitis Perennial

Interventions: Drug: fexofenadine/Allegra (M016455)

First Posted Date: 2010-11-19

Last Posted Date: 2013-10-16

Lead Sponsor: Sanofi

Target Recruit Count: 100

Registration Number: NCT01244217

Locations: 🇯🇵
Sanofi-Aventis Investigational Site Number 392015, Fukuoka-Shi, Japan
🇯🇵
Sanofi-Aventis Investigational Site Number 392003, Kawasaki-Shi, Japan
🇯🇵
Sanofi-Aventis Investigational Site Number 392004, Kawasaki-Shi, Japan

and more 12 locations

A Study of the Safety of IMOVAX Polio™ in China

Phase 4

Completed

Conditions: Poliomyelitis
Polio

Interventions: Biological: IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine

First Posted Date: 2010-11-19

Last Posted Date: 2012-08-03

Lead Sponsor: Sanofi

Target Recruit Count: 800

Registration Number: NCT01244464

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

Phase 1

Completed

Conditions: Astrocytoma, Grade IV
Glioblastoma

Interventions: Drug: XL765 (SAR245409)
Drug: XL147 (SAR245408)

First Posted Date: 2010-11-15

Last Posted Date: 2012-07-27

Lead Sponsor: Sanofi

Target Recruit Count: 40

Registration Number: NCT01240460

Locations: 🇺🇸
Investigational Site Number 840001, Los Angeles, California, United States
🇺🇸
Investigational Site Number 840003, San Francisco, California, United States
🇺🇸
Investigational Site Number 840004, Boston, Massachusetts, United States

and more 1 locations

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Phase 2

Completed

Conditions: Meningitis
Meningococcal Meningitis
Meningococcal Infections

First Posted Date: 2010-11-11

Last Posted Date: 2012-06-25

Lead Sponsor: Sanofi

Target Recruit Count: 139

Registration Number: NCT01239043

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Teriflunomide HMR1726
Drug: Cholestyramine

First Posted Date: 2010-11-11

Last Posted Date: 2012-03-01

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT01239459

Locations: 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: INSULIN GLARGINE (HOE901)
Drug: INSULIN GLULISINE (HMR1964)

First Posted Date: 2010-11-04

Last Posted Date: 2016-07-13

Lead Sponsor: Sanofi

Target Recruit Count: 219

Registration Number: NCT01234597

Locations: 🇮🇱
Investigational Site Number 376010, Tel-Aviv, Israel
🇮🇱
Investigational Site Number 376006, Netanya, Israel
🇮🇱
Investigational Site Number 376009, Sachnin, Israel

and more 8 locations

Home Terms & Conditions Privacy Policy